Business Context and Reporting Period
Company: Lucid Diagnostics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 5, 2025
Event: Closing of a public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational performance metrics. Specific figures include:
- Shares Sold: 13,939,331 shares of common stock.
- Offering Price: $1.10 per share.
- Estimated Net Proceeds: Approximately $14.5 million (after deducting placement agent fees and other expenses).
- Use of Proceeds: Working capital and general corporate purposes.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as of this date.
Material Changes
The primary material change is the increase in outstanding common stock and the influx of capital resulting from the closing of the Offering on March 5, 2025. The transaction was executed pursuant to the Company's existing shelf registration statement on Form S-3 (Registration No. 333-268560), filed in November 2022.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize the net proceeds for working capital and other general corporate purposes. The press release regarding the closing is attached as Exhibit 99.1.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard disclosure that the information furnished under Item 7.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the final net proceeds amount once all offering expenses are finalized.
- Review the attached press release (Exhibit 99.1) for details on the placement agent and specific terms of the offering.
- Confirm the updated total number of outstanding shares post-offering.
- Monitor future filings for the specific allocation of the $14.5 million in proceeds.